Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
11
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 11 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Vancomycin HCl* Vancomycin HCl | D | $52.3M | -21% | 172,023 | $304 | $3.53 |
| Vancomycin HCl Vancomycin/Water For Inj (PEG) | D | $1.7M | +38% | 5,996 | $291 | $0.09 |
| Firvanq Vancomycin HCl | D | $510K | -56% | 1,862 | $274 | $0.92 |
| Vancomycin HCl-0.9% NaCl Vancomycin/0.9 % Sod Chloride | D | $422K | -23% | 1,046 | $403 | $0.11 |
| Vancocin HCl Vancomycin HCl | D | $418K | -21% | 25 | $16,732 | $69.01 |
| Vancomycin* Vancomycin HCL In 5 % Dextrose* · J3370 | B | $159K | -16% | 5,120 | $31 | $2.38 |
| Vancomycin HCL (J3372) Vancomycin/Water For Inj (Peg) · J3372 | B | $132K | +7597% | 4,366 | $30 | $6.38 |
| Vancomycin HCl Vancomycin HCl In 5 % Dextrose | D | $122K | -24% | 347 | $351 | $0.14 |
| Vancomycin HCL (J3371) Vancomycin HCL · J3371 | B | $116K | +24430% | 5,227 | $22 | $5.79 |
| Vancomycin HCl-D5W Vancomycin HCl In 5 % Dextrose | D | $35K | +320% | 102 | $340 | $0.12 |
| Vancomycin Vancomycin HCl In 5 % Dextrose | D | $25K | -19% | 164 | $150 | $0.09 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.